Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of VQ-101 versus placebo in GBA1-associated Parkinson's disease
NL-OMON61543Phase 2Not yet recruiting
- Sponsor
- Vanqua Bio
- Start
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) and Parkinson's disease (GBA-PD) comparing VQ-101 with Placebo (2 arms). Primary endpoints: Time to clinically meaningful progression, Treatment-emergent adverse events and 2 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
VQ-101
03
Conditions
Parkinson's disease (PD)Parkinson's disease (GBA-PD)
Beyond the preview
Go deeper on NL-OMON61543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61543.